Evaluation of GvHD Damage on Medullary Mesenchymal Stem Cells

Prospective Multicenter Study for the Evaluation of GvHD Damage on Medullary Mesenchymal Stem Cells - GvHD Damage on MSCs

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05167188

Enrollment

Registered

2021-12-22

Start date

2021-10-14

Completion date

2025-03-31

Last updated

2023-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graft Vs Host Disease

Brief summary

Spontaneous, multicenter, prospective, non-pharmacological study. At the diagnosis of acute or chronic GvHD after HSCT, bone marrow cells will be analysed for MSC content and properties. Bone marrow aspirate will be performed according to usual clinical practise

Interventions

OTHERno intervention

no intervention

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

6 Months to 99 Years

Inclusion criteria

* Patients (children and adults) developing acute or chronic GvHD after HSCT. * Age 6 months- month-99 years, * Landsky-Karnofsky\> 70%, * Acute or chronic GvHD needing further immunosuppressive treatment.

Exclusion criteria

* Anything not included in the inclusion criteria.

Design outcomes

Primary

Measure	Time frame
Evaluation of damage generated by acute or chronic GvHD on the MSCs after HSCT	Through study completion, an average of 1 year

Countries

Italy

Contacts

Primary ContactFranca Fagioli, MD

franca.fagioli@unito.it+39011313

Backup ContactMassimo Berger, MD

massimoberger@gmail.com+39011313

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026